Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials. some patients do not achieve a partial response. and ultimately all patients undergo progression. https://halohealthcarers.shop/product-category/massagers/